Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Tue, 28 Jul 2026 16:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.

Content of the Notification:

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Tue, 28 Jul 2026 16:00:00 -0400

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
Content of the Notification:
- Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)
  
  Tue, 28 Jul 2026 16:00:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a transparency notification dated July 24, 2026, from Tolefi SA and related persons indicating that they have jointly crossed passively below the 10% threshold, holding 6,568,978 shares, or 8.77% of the voting rights of the Company as of July 16, 2026.
  Content of the Notification:
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
  
  Wed, 22 Jul 2026 14:45:00 -0400
  
  MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
  Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
  This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
  Figures –
  
  Celyad Oncology raises €500,000 via Fortress private placement
  
  Tue, 14 Jul 2026 03:32:18 -0400
  
  Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.
  
  Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.
  
  Following the share issuance, Fortress is expected to hold approximately 60.52% of
  
  Celyad Oncology raises €500,000 via Fortress private placement
  
  Tue, 14 Jul 2026 03:32:18 -0400
  
  Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.
  
  Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.
  
  Following the share issuance, Fortress is expected to hold approximately 60.52% of
  
  Celyad Oncology raises €500,000 via Fortress private placement
  
  Tue, 14 Jul 2026 03:32:18 -0400
  
  Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.
  
  Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.
  
  Following the share issuance, Fortress is expected to hold approximately 60.52% of
  
  Celyad Oncology raises €500,000 via Fortress private placement
  
  Tue, 14 Jul 2026 03:32:18 -0400
  
  Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.
  
  Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.
  
  Following the share issuance, Fortress is expected to hold approximately 60.52% of
  
  Celyad Oncology raises €500,000 via Fortress private placement
  
  Tue, 14 Jul 2026 03:32:18 -0400
  
  Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.
  
  Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.
  
  Following the share issuance, Fortress is expected to hold approximately 60.52% of

StreetInsider.com News Articles

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Publication of a Transparency Notification Received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

Celyad Oncology raises €500,000 via Fortress private placement

Celyad Oncology raises €500,000 via Fortress private placement

Celyad Oncology raises €500,000 via Fortress private placement

Celyad Oncology raises €500,000 via Fortress private placement

Celyad Oncology raises €500,000 via Fortress private placement